Security Snapshot

Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) Institutional Ownership

CUSIP: 140755109

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2025

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Shares outstanding
54,790,889
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • CARA - Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 140755109.
  • Latest finished 13F holder period is not available.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 1 to 0 between Q4 2024 and Q1 2025.
  • SEC-reported value moved from $7,158 to $0.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC Evidence

Security key

140755109

Latest holder period

n/a

13F holders

13D/G owners

1

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
1
Security
CARA
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Vifor (International) Ltd 14% $2,458,686 7,396,770 Vifor (International) Ltd. 17 Dec 2024

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
45
Latest
n/a
Rows shown
1-25 of 45
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q1 0 $0 -$7,158 0
2024 Q4 20,164 $7,158 -$3,973,383 $0.36 1
2024 Q3 13,514,237 $4,159,096 -$1,032,751 $0.31 65
2024 Q2 17,684,088 $4,561,540 -$4,042,593 $0.26 76
2024 Q1 23,514,485 $21,396,518 -$426,875 $0.91 96
2023 Q4 24,377,112 $18,109,185 -$5,083,037 $0.74 107
2023 Q3 27,123,062 $45,563,127 -$6,587,024 $1.68 121
2023 Q2 29,289,778 $82,888,748 -$18,896,002 $2.83 131
2023 Q1 33,889,306 $166,391,687 -$5,477,111 $4.91 161
2022 Q4 33,996,854 $365,121,945 -$4,541,381 $10.74 161
2022 Q3 34,612,850 $323,992,355 -$2,083,804 $9.36 152
2022 Q2 34,812,812 $317,864,785 +$23,430,633 $9.13 166
2022 Q1 31,735,791 $385,591,868 +$16,589,053 $12.15 177
2021 Q4 30,295,793 $368,853,803 +$3,325,166 $12.18 174
2021 Q3 29,597,983 $457,112,862 +$1,903,784 $15.45 161
2021 Q2 29,619,793 $422,555,895 -$29,484,537 $14.27 162
2021 Q1 29,844,915 $647,894,469 +$3,235,940 $21.71 156
2020 Q4 29,864,210 $451,866,505 -$10,514,992 $15.13 146
2020 Q3 30,605,125 $389,630,505 +$7,883,789 $12.72 152
2020 Q2 29,920,527 $511,617,407 +$22,432,806 $17.10 136
2020 Q1 32,217,643 $425,460,027 +$9,271,004 $13.21 130
2019 Q4 31,365,475 $505,318,090 +$4,578,062 $16.11 146
2019 Q3 30,528,396 $558,121,704 +$81,405,292 $18.28 140
2019 Q2 26,022,034 $559,418,629 +$84,321,964 $21.50 122
2019 Q1 22,307,202 $437,676,305 -$26,628,851 $19.62 130
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .